NEW YORK, Jan 20, 2026, 15:03 EST — Regular session
- OKLO dropped alongside other nuclear-focused stocks as U.S. equities slipped amid renewed trade discussions.
- Investors are still processing Oklo’s announcements from early January involving Meta and the DOE.
- Next up: funding signals followed by the upcoming quarterly update window.
Oklo Inc shares dropped Tuesday amid a wider U.S. selloff that hit high-volatility stocks hard. By 2:48 p.m. EST, the stock had fallen roughly 5.0% to $90.18, dipping as low as $88.58 earlier in the session.
Wall Street took a hit after President Donald Trump warned of fresh tariffs on imports from multiple NATO allies, shaking investor confidence. The S&P 500 tumbled roughly 1.8% in afternoon trading, per an Associated Press report.
Oklo’s stock moves more like a sentiment barometer than a typical utility. Traders react to shifts in big-tech power needs, Washington’s backing of nuclear ventures, and the ever-present question: when will the company start generating real cash flow?
Shares in other nuclear and power-related companies also took a hit. NuScale Power dropped around 5%, Vistra, a power producer, lost about 5.4%, and uranium miner Cameco edged down roughly 0.4%.
Oklo grabbed attention on Jan. 9 by announcing a deal with Meta to back the development of up to 1.2 gigawatts of nuclear power in Southern Ohio. The company plans to start pre-construction work in 2026, aiming for a first phase as early as 2030. It described the project as adding “baseload” power—constant electricity delivery—to the PJM regional grid. Meta’s Urvi Parekh summed it up as “the development of 1.2 gigawatts of nuclear energy in Southern Ohio.” Oklo
A few days ago, Oklo announced it had inked a U.S. Department of Energy “Other Transaction Agreement”—a special type of government contract—to back the design, construction, and operation of a radioisotope pilot facility under the DOE’s Reactor Pilot Program. CEO Jacob DeWitte described the deal as setting “a framework for execution and risk reduction.” The company said the facility will focus on medical and research radioisotopes, key materials used in cancer diagnosis and treatment, among other uses. Oklo also revealed it has pulled its earlier Nuclear Regulatory Commission construction permit application for the Meitner-1 commercial radioisotope project to concentrate on the pilot facility instead. Oklo
The key issue remains money. A December prospectus supplement filed with the U.S. SEC revealed Oklo could raise up to $1.5 billion by selling common stock through an at-the-market program — a setup allowing the company to sell shares gradually, which risks diluting current shareholders. The filing also cautioned about potential unexpected costs and construction delays as initial projects shift from planning to actual construction.
Traders are focused on whether Tuesday’s sudden risk-off move in nuclear-themed stocks will stick around or vanish just as quickly. When it comes to Oklo, the stock reacts immediately to any news of new funding, delays, or customer deals—before the discussion even begins.
Oklo hasn’t announced when it will release its next earnings, but MarketBeat projects it will be March 23 after the market closes, following its usual schedule. Investors will be watching closely for any news on cash burn or project timelines, which could drive OKLO’s stock next.
